Skip to main content

AGEN

Stock
Health Care
Biotechnology

Performance overview

AGEN Price
Price Chart

Forward-looking statistics

Beta
1.70
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Company info

SectorHealth Care
IndustryBiotechnology
Employees348
Market cap$348.6M

Fundamentals

Enterprise value$218.3M
Revenue$99.5M
Revenue per employee—
Profit margin-191.50%
Debt to equity-0.29

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$29.61
Dividend per share—
Revenue per share$4.42
Avg trading volume (30 day)$8M
Avg trading volume (10 day)$7M
Put-call ratio—

Macro factor sensitivity

Growth+12.0
Credit+28.0
Liquidity-15.7
Inflation+3.2
Commodities+4.0
Interest Rates-1.0

Valuation

Dividend yield0.00%
PEG Ratio-0.63
Price to sales1.67
P/E Ratio-0.63
Enterprise Value to Revenue2.19
Price to book-0.02

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Here is how Agenus (AGEN) and CVS Health (CVS) have performed compared to their sector so far this year.

Zacks Investment Research (July 14, 2025)
3 Top Earnings Acceleration Stocks to Buy for 2H25

Yext, Agenus and NCR Voyix show accelerating earnings growth, making them standout picks for the second half.

Zacks Investment Research (July 8, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free